glp 1 drugs in development Glucagon-like peptide-1 receptor: mechanisms and advances therapy The Multi-Sector Impacts of GLP-1RA
Description
This stands in contrast to the hepatotoxicity that terminated Pfizer's danuglipron and lotiglipron programs
Our specialists carefully monitor each patient to ensure safe use and adjust treatment as needed
However, the impact of weight on RA doesnt stop at disease onset
10.1016/j.jad.2012.01.013 [DOI] [PubMed] [Google Scholar] Zheng P., Zeng B., Zhou C., Liu M., Fang Z., Xu X., et al
Nat Rev Endocrinol (2019) 15:28898
doi: 10.1124/pr.55.1.6 [DOI] [PubMed] [Google Scholar] 79.Korner M, Stockli M, Waser B, Reubi JC
